Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1346-1352

  Moulder, Stacy ^a   Helgason, T ^a   Janku, F ^a   Wheler, J ^a   Moroney, J ^a   Booser, D ^a   Albarracin, C ^a   Morrow, P K ^a   Atkins, J ^a   Koenig, K ^a   Gilcrease, M ^a   Kurzrock, R ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bevacizumab; Liposomal doxorubicin; Metaplastic breast cancer; Temsirolimus

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RAPAMYCIN;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; METASTATIC METAPLASTIC BREAST CANCER; MONOTHERAPY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NF2 GENE; ONCOGENE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPLETION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; DRUG EFFECTS; FEMALE; FOLLOW UP; GENETICS; MESODERM; METABOLISM; METAPLASIA; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CARBOPLATIN; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MESODERM; METAPLASIA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SIROLIMUS; SURVIVAL RATE; YOUNG ADULT;

EID: 84942096399     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv163     Document Type: Article

References (30)

1. Tse GM, Tan PH, Putti TC et al. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol 2006; 59: 1079-1083.
2. Hennessy BT, Giordano S, Broglio K et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 2006; 17: 605-613.
3. Jung SY, Kim HY, Nam BH et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 2010; 120: 627-637.
4. Luini A, Aguilar M, Gatti G et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2007; 101: 349-353.
5. Rayson D, Adjei AA, Suman VJ et al. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 1999; 10: 413-419.
6. Barnes PJ, Boutilier R, Chiasson D, Rayson D. Metaplastic breast carcinoma:clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat 2005; 91: 173-178.
7. Lester TR, Hunt KK, Nayeemuddin KM et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 2012; 131: 41-48.
8. Herschkowitz JI, Simin K, Weigman VJ et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
9. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
10. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68.
11. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-4124.
12. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
13. Moulder S, Moroney J, Helgason T et al. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol 2011; 29: e572-e575.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Janku F, Tsimberidou AM, Garrido-Laguna I et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10: 558-565.
16. Janku F, Wheler JJ, Naing A et al. PIK3CA mutations in advanced cancers:characteristics and outcomes. Oncotarget 2012; 3: 1566-1575.
17. Janku F, Wheler JJ, Naing A et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013; 73: 276-284.
18. Moroney JW, Schlumbrecht MP, Helgason T et al. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 2011; 17: 6840-6846.
19. Al Sayed AD, El Weshi AN, Tulbah AM et al. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol 2006; 45: 188-195.
20. Holsinger FC, Piha-Paul SA, Janku F et al. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol 2013; 31: e137-e140.
21. Janku F, Wheler JJ, Westin SN et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-782.
22. Bellino R, Arisio R, D'Addato F et al. Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res 2003; 23: 669-673.
23. Kochhar R, Howard EM, Umbreit JN, Lau SK. Metaplastic breast carcinoma with squamous differentiation: molecular and clinical analysis of six cases. Breast J 2005; 11: 367-369.
24. Lopez-Lago MA, Okada T, Murillo MM et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 29: 4235-4249.
25. Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.
26. Subbiah V, Slopis J, Hong DS et al. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 2012; 30: e64-e68.
27. Plotkin SR, Merker VL, Halpin C et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33: 1046-1052.
28. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, II et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361: 358-367.
29. James MF, Han S, Polizzano C et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009; 29: 4250-4261.
30. James MF, Stivison E, Beauchamp R et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res 2012; 10: 649-659.